13.3 Childhood Infections, Exanthems & Caribbean Immunisation Schedules

Clinical Assessment & Differential Diagnosis of Childhood Exanthems

Childhood fevers accompanied by acute cutaneous eruptions (exanthems) and mucosal lesions (enanthems) represent common diagnostic challenges in Caribbean paediatric practice. Accurate bedside differentiation prevents secondary transmission of vaccine-preventable diseases, guides post-exposure prophylaxis, and protects vulnerable populations, such as pregnant women and children with sickle cell disease.

1. Measles (Rubeola): 3 Cs, Koplik Spots & High-Dose Vitamin A

• Etiology & Transmission: Measles virus is a negative-sense single-stranded RNA Paramyxovirus (genus Morbillivirus). It is one of the most contagious human pathogens known, boasting a basic reproduction number ($R_0$) of 12 to 18. Transmission occurs via airborne respiratory droplet nuclei that remain suspended and infectious in ambient air for up to 2 hours. Incubation period is 10 to 14 days.
• The Prodromal Phase: Characterized by 3 to 4 days of escalating high fever (often reaching 39.5°C to 40.5°C) accompanied by the pathognomonic "Three Cs":
  1. Cough (harsh, dry, hacking brassy cough).
  2. Coryza (profuse, clear-to-mucopurulent rhinorrhea).
  3. Conjunctivitis (marked bilateral bulbar conjunctival injection, lacrimation, and severe photophobia).
• The Enanthem (Koplik Spots): Appearing 24 to 48 hours before the cutaneous rash, Koplik spots are pathognomonic for measles. They present as tiny (1 to 2 mm), irregular, clustered bluish-white or greyish-white grains resembling salt or sugar granules, situated on an erythematous, inflamed mucosal base on the buccal mucosa opposite the second lower molars. They persist for 24 to 48 hours and fade as the cutaneous exanthem reaches full bloom.
• The Cutaneous Exanthem: An intensely erythematous, blanching, non-pruritic maculopapular rash that originates at the hairline, retroauricular regions, and upper neck. Over the subsequent 3 days, it progresses strictly cephalocaudally over the face, neck, trunk, upper extremities, abdomen, and lower extremities to reach the feet. As it spreads downward, earlier facial lesions become confluent and non-blanching. The rash lasts 5 to 7 days, clearing in the same order of appearance (head down), leaving a fine branny desquamation and a characteristic brownish-copper hyperpigmentation (staining).
• High-Yield Complications:
  • Otitis Media: The most common overall complication (affecting ~10% of cases).
  • Pneumonia: The leading cause of measles-related death in young children. May occur as primary viral giant-cell pneumonia (Hecht's pneumonia) or secondary bacterial superinfection (S. pneumoniae, S. aureus, H. influenzae).
  • Acute Disseminated Encephalomyelitis (ADEM): Post-infectious autoimmune demyelination occurring in 1 in 1,000 cases, manifesting 1 to 2 weeks post-rash.
  • Subacute Sclerosing Panencephalitis (SSPE): A devastating, fatal neurodegenerative disease occurring 7 to 10 years after primary infection, caused by persistent, mutated defective measles virus replication in the central nervous system (insidious cognitive decline, myoclonic jerks, ataxia, coma).
• WHO Vitamin A Therapy: The World Health Organization mandates that all children with acute measles receive high-dose oral Vitamin A once daily for 2 consecutive days, regardless of their nutritional status:
  • 50,000 IU for infants < 6 months of age.
  • 100,000 IU for infants aged 6 to 11 months.
  • 200,000 IU for children aged 12 months and older.
  • Rationale: Measles virus depletes serum retinol and damages respiratory and intestinal epithelial integrity. Vitamin A accelerates mucosal epithelial regeneration, enhances antibody responses, prevents xerophthalmia/keratomalacia blindness, and reduces measles mortality by over 50%.

2. Rubella (German Measles): Adenopathy & Congenital Rubella Syndrome

• Etiology & Clinical Features: Caused by the Rubella virus (a positive-sense ssRNA rubivirus of the family Matonaviridae). Transmitted via respiratory droplets; incubation period 14 to 21 days. In children, it is typically a mild, self-limiting "three-day" illness with low-grade fever, mild coryza, and prominent, tender suboccipital, postauricular, and posterior cervical lymphadenopathy, which characteristically precedes the exanthem by 24 to 48 hours.
• Enanthem & Exanthem:
  • Forchheimer Spots: Tiny rose-red macules or petechiae on the soft palate and uvula seen in 20% of patients during the prodrome (non-pathognomonic).
  • Exanthem: Discrete, pinpoint, rose-pink maculopapular rash that originates on the face and spreads rapidly downward to the trunk and extremities within 24 hours. The rash does not coalesce like measles and typically fades completely by day 3 ("3-day measles") without significant desquamation.
• Congenital Rubella Syndrome (CRS): While postnatal rubella is benign, primary maternal infection during the first trimester (especially weeks 1 to 8) produces devastating teratogenic organogenesis failure in > 85% of fetuses. The classic Gregg Clinical Triad of CRS comprises:
  1. Sensorineural Hearing Loss (the most common single manifestation, occurring in > 60% of affected infants).
  2. Ocular Defects: Congenital cataracts (dense pearl-white nuclear opacities, frequently bilateral), microphthalmia, and "salt-and-pepper" pigmentary retinopathy.
  3. Congenital Heart Defects: Patent Ductus Arteriosus (PDA) and peripheral pulmonary artery stenosis.
  • Additional Signs: Intrauterine growth restriction, microcephaly, hepatosplenomegaly, radiolucent "celery stalk" metaphysis bone lesions, and dermal erythropoiesis producing a characteristic "Blueberry Muffin" purpuric rash.

3. Varicella (Chickenpox): Polymorphic Crops & Invasive Bacterial Superinfections

• Etiology & Evolution: Varicella-Zoster Virus (VZV / Human Herpesvirus 3), a double-stranded DNA alphaherpesvirus. Highly contagious via airborne droplet nuclei and direct contact with open vesicle fluid (infectious from 48 hours before rash until all vesicles have crusted). Incubation period 10 to 21 days.
• Cutaneous Morphology: Following a brief prodrome of low fever and malaise, the rash emerges on the scalp, face, and trunk before spreading to the extremities, with the greatest concentration on the trunk (a centripetal distribution). Lesions progress rapidly through distinct stages within 8 to 12 hours: pruritic rose-red macule $\rightarrow$ papule $\rightarrow$ thin-walled clear vesicle on an intensely erythematous base ("dewdrops on a rose petal") $\rightarrow$ cloudy pustule $\rightarrow$ umbilicated central depression $\rightarrow$ dry crusted scab.
• Hallmark Feature: The rash erupts in successive "crops" over 3 to 5 days, so that all stages of lesion development (macules, papules, active vesicles, and crusting scabs) are present simultaneously within the same anatomical region.
• Complications: Secondary bacterial skin and soft-tissue infections caused by Staphylococcus aureus or Streptococcus pyogenes (Group A Strep) are the most frequent complications. Warning signs include surrounding erythema, warmth, pain, and persistent high fever beyond day 3, which can rapidly progress to necrotizing fasciitis or toxic shock syndrome. Other complications include post-infectious acute cerebellar ataxia (self-limiting ataxia and nystagmus developing 1 to 3 weeks post-infection), varicella pneumonitis (common in adults/smokers), and Reye syndrome if aspirin is administered.

4. Erythema Infectiosum (Fifth Disease): Parvovirus B19 & Aplastic Crisis

• Etiology & Tropism: Parvovirus B19 is a small, non-enveloped single-stranded DNA virus. Transmitted via respiratory droplets with an incubation period of 4 to 14 days. The virus exhibits exquisite, selective cytotoxicity for human erythroid progenitor cells (proerythroblasts) in the bone marrow, binding specifically to the erythrocyte P antigen (globoside) receptor. Viral replication lyses erythroid precursors, temporarily halting red blood cell production for 7 to 10 days.
• Biphasic Clinical Presentation:
  • Stage 1 (Slapped-Cheek Appearance): Begins with mild prodromal fever, malaise, and headache. After 2 to 5 days, a fiery red, confluent maculopapular erythema erupts over both cheeks with conspicuous circumoral pallor (resembling the mark of an open-hand slap).
  • Stage 2 (Lacy Reticular Rash): One to four days later, an erythematous maculopapular eruption appears on the trunk and proximal extremities, which clears centrally to produce a classic reticular, lace-like, or fishnet appearance. The rash is non-pruritic, spares the palms and soles, and can wax and wane for 1 to 3 weeks, characteristically re-emerging with environmental heat, hot baths, sunlight, or physical exertion. The child is no longer contagious once the rash appears.
• CRITICAL CARIBBEAN COMPLICATION: Transient Aplastic Crisis (TAC):
  • In healthy children with normal red cell survival (120 days), a 7-day cessation of erythropoiesis produces only a negligible, subclinical dip in hemoglobin.
  • However, in children with chronic hemolytic disorders—most notably Sickle Cell Disease (HbSS, HbSC), beta-thalassemia, or hereditary spherocytosis, whose red cell lifespans are shortened to 10 to 20 days—Parvovirus B19 infection causes an acute, life-threatening Transient Aplastic Crisis.
  • Clinical Picture: Precipitous drop in hemoglobin (often falling to 2 to 4 g/dL), severe pallor, lethargy, tachycardia, high-output congestive heart failure, and profound reticulocytopenia (reticulocyte count < 0.1% or < 10,000/uL). The key is an acute hemoglobin fall with profound reticulocytopenia; baseline jaundice may persist. Acute splenic enlargement instead suggests sequestration; assess transfusion history and hemolysis markers if hyperhemolysis is suspected. Management requires urgent hospitalization, isolation (droplet precautions), and packed red blood cell transfusion.
  • Pregnancy Risk: Primary maternal Parvovirus B19 infection during the second trimester causes fetal anemia, high-output fetal cardiac failure, generalized subcutaneous edema, ascites, non-immune hydrops fetalis, and intrauterine fetal demise.

5. Roseola Infantum (Exanthem Subitum): HHV-6 & Febrile Seizures

• Etiology & Demographics: Caused by Human Herpesvirus 6 (HHV-6B), and less commonly HHV-7. Almost exclusively affects infants and young toddlers between 6 and 15 months of age (rare after 2 years), following the waning of protective transplacental maternal antibodies.
• The Pathognomonic Clinical Sequence: Roseola follows an unforgettable "fever breaks, rash emerges" clinical trajectory:
  1. High Sustained Fever: Abrupt onset of high fever (39.5°C to 40.5°C) lasting precisely 3 to 5 days. Despite the extreme pyrexia, the infant is typically remarkably alert, interactive, and playful, with minimal physical findings aside from mild pharyngeal hyperemia or faint erythematous palatal papules (Nagayama spots).
  2. Sudden Defervescence & Rash Emergence: On day 4 or 5, the fever drops precipitously (defervescence) to normal within hours. Simultaneously, an exanthem erupts: a discrete, rose-pink, non-pruritic, blanching maculopapular rash that appears primarily on the trunk and neck, with minimal spread to the face and proximal extremities. The rash fades within 24 to 48 hours without desquamation or staining.
• Primary Complication: Febrile Seizures. Because HHV-6 is neurotropic and provokes rapid temperature spikes, it is the single most common viral cause of febrile status epilepticus and simple febrile seizures in infants under 2 years of age.

6. Hand, Foot, and Mouth Disease (HFMD): Enterovirus Neurovirulence

• Etiology: Caused by human enteroviruses of the Picornaviridae family, most commonly Coxsackievirus A16 and Enterovirus A71 (EV-A71). Incubation period 3 to 6 days.
• Clinical Manifestations: Begins with low-grade fever, anorexia, and sore mouth. Within 1 to 2 days, characteristic lesions develop:
  • Oral Enanthem: Small erythematous macules that rapidly ulcerate into shallow, painful 2 to 4 mm vesicles with red erythematous halos located on the buccal mucosa, tongue, hard palate, and gingiva, leading to significant dysphagia and drooling.
  • Cutaneous Exanthem: Painless, non-pruritic, oval or elliptical 2 to 5 mm greyish-white papules and vesicles with a surrounding red erythematous rim, distributed primarily on the palms of the hands, soles of the feet, interdigital spaces, and buttocks.
• EV-A71 Neurovirulence: While Coxsackievirus A16 causes mild, self-limiting disease resolving in 7 to 10 days, Enterovirus A71 strains are neurovirulent and have caused major epidemics associated with brainstem encephalitis, acute flaccid myelitis/paralysis, autonomic instability, and catastrophic neurogenic pulmonary edema.

Diagnostic Differentiation Matrix of Classic Childhood Exanthems

The Caribbean Expanded Program on Immunization (EPI) Schedule

Immunization programs in the English-speaking Caribbean are coordinated under the auspices of the Pan American Health Organization (PAHO) and the Caribbean Public Health Agency (CARPHA). The Americas were certified polio-free in 1994, achieved verification of rubella and congenital rubella syndrome elimination in 2015, and verified measles elimination in 2016. These historical milestones require sustained vaccination and surveillance.

National EPI Schedules: Jamaica and Trinidad and Tobago

There is no single Caribbean vaccination timetable. National ministries set the schedule, formulations, eligibility and catch-up rules; use the schedule for the jurisdiction in the question. The following published national schedules illustrate important differences:

Clinical use: Review the child's immunisation card, identify which national schedule applies, and distinguish routine doses from catch-up and risk-based doses. Do not assume that BCG, rotavirus, varicella, a particular PCV valency, or a hexavalent product is routinely offered at the same age in every territory. Vaccine volumes and routes depend on the supplied formulation; use its administration instructions.

National sources: Jamaica immunisation information and Trinidad and Tobago immunisation brochure.

• BCG Vaccine: Live-attenuated Mycobacterium bovis administered at birth intradermally over the right deltoid insertion. Induces cell-mediated immunity protecting infants against tuberculous meningitis and miliary tuberculosis. Produces a local papule at 2 to 4 weeks that ulcerates and heals with a permanent scar by 8 to 12 weeks.
• Hepatitis B: The birth dose must be administered within 24 hours of life to prevent vertical mother-to-child transmission, which carries a 90% risk of progressing to chronic hepatitis B, cirrhosis, and hepatocellular carcinoma.
• Pneumococcal Conjugate Vaccine (PCV13): Protects against 13 serotypes responsible for invasive pneumococcal disease (meningitis, bacteremia, bacteremic pneumonia) and acute otitis media.
• Rotavirus Vaccine: Give orally, using the national schedule and age limits. The ACIP schedule starts the series by 14 weeks 6 days and completes it by 8 months 0 days. WHO recommends catch-up for missed doses in children younger than 24 months; apply the jurisdiction's policy rather than treating the ACIP cutoffs as a worldwide prohibition.

Vaccine Storage, Cold Chain Integrity & Clinical Safety Rules

Cold Chain Maintenance & The Shake Test

Vaccine efficacy relies on an unbroken Cold Chain from manufacturing to administration. In tropical Caribbean environments, strict refrigeration protocols are vital:

• Refrigerated Vaccines (+2°C to +8°C): DTaP, Hepatitis B, Hib, IPV, PCV13, and HPV must be maintained strictly between +2°C and +8°C. They must NEVER BE FROZEN.
• Freezing Damage & The Shake Test: Freezing can irreversibly damage adsorbed vaccines, reduce their potency and increase local reactions. For a vaccine suitable for the Shake Test, compare the suspect vial with a vial of the same vaccine, manufacturer and batch that has deliberately been frozen solid and then thawed. Label this control so it cannot be administered. Shake both together for 10–15 seconds, stand them side by side, and compare sedimentation. If the suspect vial sediments as fast as or faster than the frozen control, do not use it; quarantine the affected stock and notify the immunisation supervisor. Slower sedimentation passes the test. The test is not applicable to IPV.
• Light Sensitivity & Reconstitution: Protect MMR and varicella vaccines from light and use them promptly after reconstitution. Follow the supplied product's discard time: reconstituted varicella generally must be used within 30 minutes; do not apply a six-hour MMR/session rule to varicella.

Live-Attenuated Vaccine Scheduling & Immunodeficiency Contraindications

• Interval Rule for Live Vaccines: Live injected vaccines (MMR, Varicella, Yellow Fever) must be administered either simultaneously on the same calendar day (at separate anatomical injection sites) OR separated by an absolute minimum interval of 28 days (4 weeks). If separated by fewer than 28 days, interferon release from the first vaccine neutralizes the second, causing immunogenic failure.
• Absolute Contraindications to Live Vaccines:
  1. Severe Primary or Acquired Immunodeficiency: Severe Combined Immunodeficiency (SCID), active leukemia, lymphoma, or advanced HIV infection with severe CD4 T-lymphocyte depletion (for MMR: CD4 <15% at age <=5 years; at >5 years, CD4 <15% or <200 cells/uL; recovery to >=15% and, if >5 years, >=200 cells/uL must persist >=6 months).
  2. High-Dose Systemic Corticosteroid Therapy: Prednisone >= 2 mg/kg/day or >= 20 mg/day for 14 or more consecutive days. Live vaccines must be deferred for at least 1 month following steroid cessation.
  3. Pregnancy: Theoretical risk of teratogenic fetal infection.
  4. Recent Blood Product / Immunoglobulin Administration: Passively acquired maternal or donor antibodies neutralize live vaccine replication. MMR and Varicella must be deferred for 3 to 11 months (depending on the dose of IVIG, packed red cells, or plasma received).

Management of Vaccine Anaphylaxis

True anaphylaxis occurs in approximately 1 to 2 per million doses. Emergency management mandates:

1. Place the child supine with legs elevated.
2. Immediate Intramuscular Epinephrine (1:1,000 / 1 mg/mL): Administer 0.01 mg/kg (0.01 mL/kg), maximum dose 0.3 mg in prepubertal children (0.5 mg in adolescents), injected into the anterolateral aspect of the middle third of the thigh (vastus lateralis). Repeat every 5 to 15 minutes as needed.
3. High-flow oxygen via non-rebreather face mask.
4. Intravenous fluid resuscitation with isotonic normal saline for refractory hypotension.